Menu
Annual · values202520242023202220212020201920182017201620152014
Operating Cash Flow148261 USD-466362 USD-699686 USD-409545 USD-249838 USD-42260 USD608312 USD1.26 M USD841216 USD2.90 M USD3.35 M USD4.57 M USD
Depreciation & Amortization1.50 M USD2.62 M USD2.75 M USD2.70 M USD3.09 M USD2.68 M USD2.93 M USD3.26 M USD3.29 M USD3.08 M USD3.60 M USD1.79 M USD
Stock-Based Compensation
Capital Expenditures59324 USD38411 USD11517 USD401964 USD438055 USD867307 USD136003 USD51145 USD136479 USD-193404 USD685302 USD-5.13 M USD
Cash Flow from Investing-137251 USD-291718 USD-11517 USD-401964 USD-438055 USD-867307 USD-136003 USD-51145 USD-136479 USD-193404 USD-1.90 M USD-5.84 M USD
Cash Flow from Financing-294027 USD27353 USD73145 USD-1.77 M USD4.60 M USD624177 USD-1.73 M USD-1.98 M USD-1.48 M USD-6.02 M USD0 USD605002 USD
Dividends Paid
Stock Buybacks
Free Cash Flow88937 USD-504773 USD-711203 USD-811509 USD-687893 USD-909567 USD472309 USD1.21 M USD704737 USD3.09 M USD2.66 M USD9.70 M USD

China Pharma Holdings Inc. is a provider of pharmaceutical products known for its focus on the development, production, and marketing of generic and specialty drugs. The company operates primarily within the healthcare and pharmaceutical sectors, contributing significantly to the medical supply chain. Its portfolio includes a diverse range of products that address common health needs such as antibiotics, cardiovascular medications, and pain relief, positioning it as a crucial player in providing affordable healthcare solutions. China Pharma Holdings Inc. is particularly impactful in the Chinese market, leveraging extensive research and development capabilities to introduce effective treatment options. The company's operations are not just limited to drug manufacturing; they also involve significant efforts in distribution to ensure widespread accessibility of their medicines. With an aging global population and increasing demand for cost-effective healthcare solutions, China Pharma plays a vital role in meeting these needs, enhancing the treatment landscape not only in China but also in other countries. By adhering to stringent quality standards and regulatory compliances, China Pharma Holdings Inc. reinforces its commitment to improving health outcomes across its operational markets.